10-Q: Celularity Faces Delisting Amidst Q1 Revenue Drop, Liquidity Concerns

Celularity Inc. reported a significant revenue decline and increased operating losses in Q1 2025, raising substantial doubt about its ability to continue as a going concern, compounded by a Nasdaq delisting notice.

Summary

• Net revenues for Q1 2025 decreased by 22.2% to $11.4 million from $14.7 million in Q1 2024.
• Product sales declined by 29.8% to $9.0 million, primarily due to lower Biovance 3L sales, partially offset by higher Rebound sales.
• Operating loss increased by 42.2% to $10.5 million in Q1 2025, compared to $7.4 million in Q1 2024.
• Net loss for Q1 2025 was $19.8 million, a slight improvement from $22.0 million in Q1 2024.
• Cash and cash equivalents stood at $0.3 million as of March 31, 2025, down from $0.7 million at December 31, 2024.
• The company has an accumulated deficit of $919.5 million as of March 31, 2025.
• Net cash used in operating activities improved to $3.0 million in Q1 2025 from $4.4 million in Q1 2024.
• Total debt was $43.1 million as of March 31, 2025.
• Nasdaq issued a delisting notice on May 28, 2025, for failure to timely file the Q1 2025 10-Q, with an extension granted until August 31, 2025.
• Subsequent to the quarter, the company raised approximately $1.035 million and $2.0 million through private placements in June and July 2025, respectively.
• An Asset Purchase Agreement on August 13, 2025, for $33.8 million from Celeniv Pte. Ltd. was used to fully repay $27.0 million of RWI Bridge Loans and a $6.8 million promissory note to Lim Kok Thay.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, a 'going concern' doubt, declining revenues, increasing operating losses, and a Nasdaq delisting notice. While some debt was repaid through an asset sale and new capital was raised, these actions appear reactive to critical financial distress rather than indicative of strong operational health or strategic growth. The material weaknesses in internal controls further compound the negative outlook.

Positives

• Net cash used in operating activities decreased to $3.0 million in Q1 2025 from $4.4 million in Q1 2024, indicating improved operational cash burn.
• License, royalty, and other revenues increased by 81.5% to $1.0 million in Q1 2025.
• Research and development expenses decreased by 36.2% to $3.7 million in Q1 2025, reflecting reprioritization efforts.
• Successful repayment of significant debt obligations totaling $33.8 million (RWI Bridge Loans and Lim Kok Thay promissory note) through an asset sale in August 2025.
• Secured extensions for the Yorkville convertible promissory note, first to August 15, 2025, then to October 15, 2025 (conditional).
• Nasdaq granted an exception until August 31, 2025, to regain compliance with listing requirements.
• Successful private placements in June and July 2025, raising approximately $1.035 million and $2.0 million, respectively.
• Conversion of unsecured senior convertible notes into 490,632 shares of Class A common stock, reducing debt.

Negatives

• Net revenues decreased by 22.2% to $11.4 million in Q1 2025 compared to $14.7 million in Q1 2024.
• Product sales, primarily Biovance 3L, decreased by 29.8% to $9.0 million.
• Operating loss increased by 42.2% to $10.5 million in Q1 2025.
• Cash and cash equivalents significantly declined to $0.3 million as of March 31, 2025, from $0.7 million at December 31, 2024.
• Accumulated deficit reached $919.5 million as of March 31, 2025.
• Substantial doubt about the company's ability to continue as a going concern due to significant operating losses and insufficient cash.
• Received a Nasdaq delisting notice for failure to timely file the Q1 2025 10-Q.
• Increased cost of revenues by 117% to $3.6 million, including a $0.7 million write-off of Interfyl bulk material costs.
• Interest expense more than doubled to $2.4 million in Q1 2025 from $1.1 million in Q1 2024.
• Loss on debt extinguishment increased by 46.8% to $5.7 million in Q1 2025.
• Defaulted on payments for a settlement agreement with TCWGlobal, resulting in a $350k judgment.
• Defaulted on answering a complaint from Clinical Resource Network for $176k.
• Not actively developing cellular therapeutics in the pipeline due to liquidity constraints.

Risks

• Substantial doubt about the ability to continue as a going concern, potentially affecting future financing and requiring curtailment of operations or bankruptcy.
• Need to raise additional capital, which may not be available on acceptable terms or at all, leading to delays, limitations, or termination of operations.
• Risk of delisting from Nasdaq if compliance with listing requirements is not maintained by August 31, 2025.
• Significant decline in sales of commercial biomaterial products could harm the business.
• Challenges in obtaining regulatory approval for novel placental-derived cellular therapy candidates.
• Reliance on third-party distribution arrangements for biomaterials products, with risks of unmet demand forecasts or inability to meet demand.
• Potential impact on commercial biomaterials business if regulatory authorities determine products do not qualify for reimbursement (e.g., CMS rejecting Interfyl claims).
• Reliance on third parties for clinical trials, with risks of failure to meet deadlines or contractual duties.
• Lengthy and time-consuming FDA regulatory approval process for therapeutic candidates.
• Manufacturing or other failures at the company's own facility could adversely affect clinical trials and commercial viability.
• Dependence on donors of healthy human full-term post-partum placentas for manufacturing.
• Clinical trials may fail to demonstrate safety and/or efficacy of therapeutic candidates.
• Inadequate protection of intellectual property could hinder competition.
• Disputes with third parties regarding agreements, payment obligations, or intellectual property rights.
• Therapeutic candidates may cause undesirable side effects.
• Significant competition from other biotechnology and pharmaceutical companies.
• Exposure to numerous laws and regulations regarding relationships with customers, physicians, and third-party payors, with potential for substantial penalties for violations.
• Adverse effects from health pandemics, geopolitical conflicts, inflation, bank failures, and recessions.
• Significant costs and management time required for operating as a public company and compliance initiatives.
• Material weaknesses in internal control over financial reporting, impacting financial reporting reliability.
• Uncertainty regarding potential liability from a Civil Investigative Demand under the False Claims Act.
• Risk of not recovering $2.35 million from Evolution Biologyx, LLC, and defending against their counterclaims.
• Risk of further legal judgments for unpaid invoices (e.g., TCWGlobal, Hackensack Meridian, Clinical Resource Network).
• The impact of the One Big Beautiful Bill Act (OBBBA) on deferred tax balances is still being evaluated.
• The company is not actively developing cellular therapeutics in its pipeline due to liquidity constraints.

Future Outlook

The company expects to continue incurring significant operating losses and using net cash for operations. It needs to secure additional outside capital to fund investments and meet obligations, with no assurance it will be secured on acceptable terms. The company plans to submit a 510(k) application for Celularity Tendon Wrap (CTW) in the second half of 2025, advance FUSE Bone Void Filler for a 510(k) filing in the second half of 2026, and Celularity Placental Matrix (CPM) for a 510(k) filing in the second half of 2027. When sufficiently capitalized, it plans to complete safety and efficacy assessments for PDA 001 in Crohn's disease and PDA 002 in DFU to determine progress to Phase III clinical trials. The company is also assessing opportunities to supply MLASCs cell therapy product candidates in states with expanded access laws, such as Florida.

Management Comments

• Our goal is to ensure all individuals have the opportunity to live healthier longer.
• We believe that by harnessing the placentas unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible and affordable therapeutics.
• We are actively assessing opportunities in Florida and elsewhere to supply our MLASCs cell therapy product candidates PDA 001 and PDA 002 to physicians for use in accordance with state law.
• When we are sufficiently capitalized, we plan to complete our safety and efficacy assessment to determine progress to a Phase III clinical trial of, respectively, our MLASCs cell therapy product candidate PDA 001 in Crohns disease and our MLASCs cell therapy product candidate PDA 002 in DFU.
• We expect that as a result of our reprioritization efforts, we will see a decrease in our selling, general and administrative costs in the near term.
• To date, we have not had any cellular therapeutics approved for sale and have not generated any revenues from the sale of our cellular therapeutics and we are not actively developing any cellular therapeutics in our pipeline given our liquidity.

Industry Context

Celularity operates in the highly competitive and capital-intensive biotechnology industry, focusing on cell therapy and regenerative medicine. The company's strategy to leverage placental-derived allogeneic cells for cancer, infectious, and degenerative diseases represents a novel approach. The recent Florida law expanding access to stem cell therapies highlights a potential market opportunity for companies like Celularity, though regulatory hurdles remain significant. The company's shift towards contract manufacturing and development services for third parties indicates an adaptation to market needs and a strategy to generate revenue while its own therapeutic candidates are in early development or stalled due to liquidity. The ongoing challenges with regulatory approvals and the need for substantial capital are common themes in the early-stage biotech sector.

Comparison to Industry Standards

• The company's accumulated deficit of over $919 million and continued operating losses are typical for early-stage biotechnology companies heavily invested in R&D, but the magnitude indicates significant capital consumption without commercialized cellular therapeutics.
• The reliance on multiple debt financings, warrant issuances, and private placements is a common strategy for biotech firms to fund operations and clinical trials, but the frequent need for extensions and modifications suggests ongoing financial strain compared to more established industry players.
• The Nasdaq delisting notice for late filing is a serious governance issue, indicating a failure to meet basic public company compliance standards, which is below industry best practices.
• The company's intellectual property portfolio of over 290 patents and applications is substantial for a biotech firm, suggesting a strong foundation in its core technology, comparable to other innovative players in the cell therapy space.
• The company's biomaterials business (Biovance, Interfyl, Rebound) provides some commercial revenue, which is a differentiator from pure-play clinical-stage biotechs, offering a more diversified revenue stream, though product sales are declining.
• The termination of the Regeneron Services Agreement, while generating some deferred revenue recognition, indicates a potential setback in a key collaboration, which can be a significant blow for smaller biotech firms relying on partnerships.

Management Changes

Corporate Governance

Legal Proceedings

• Civil Investigative Demand under the False Claims Act from the U.S. Attorney's Office for the Eastern District of Pennsylvania, requesting documents related to claims for injectable human tissue therapy products (including Interfyl). The matter is in preliminary stages with uncertain liability.
• Celularity Inc. v. Evolution Biologyx, LLC, et al.: Company filed a complaint seeking $2,350k for unpaid biomaterial product invoices. Evolution filed a counterclaim alleging breach of contract, warranty, quasi-contract, and fraud.
• TargetCW v. Celularity Inc.: TCWGlobal filed a complaint for breach of contract for unpaid services. A settlement agreement for $516k was reached, but the company defaulted on payments. A motion to enforce settlement was granted, and judgment was entered for $350k against the company on June 3, 2025.
• Hackensack Meridian v. Celularity Inc.: HUMC filed a complaint seeking $946k for clinical trial costs. The company believes there are improper charges and has accrued $668k. HUMC has moved for entry of default.
• Clinical Resource Network v. Celularity Inc.: CRN filed a complaint seeking $176k for unpaid payrolling services. The company defaulted, and CRN moved for entry of default on July 23, 2025.

Related Party Transactions

• Dr. Robert Hariri (Chairman and CEO): Salary reduction to minimum wage with deferral until December 31, 2023, then 85% reduction effective February 16, 2024, with a bonus program for unpaid salary (125%) upon achieving specific equity financing conditions. Full base salary resumed January 1, 2025. Loan agreement on August 21, 2023, for $1,000k at 15% interest, maturity extended to December 31, 2025. Assumed loans of two unaffiliated lenders from an August 21, 2023, agreement. Promissory note on October 12, 2023, for $285k at 15% interest, maturity extended to December 31, 2025.
• Alexandra Hariri (Executive Director, Corporate Strategy & Business Development): Daughter of Dr. Robert Hariri, annual base salary of $265k for 2025 and 2024, eligible for bonus, equity, and benefits on similar terms as other employees.
• C.V. Starr & Co., Inc. (C.V. Starr): Stockholder and lender. Loan agreement (Starr Bridge Loan) for $5,000k on March 17, 2023, with warrants. Maturity extended to February 15, 2026. Loan fully repaid on July 29, 2025, for $5,900k using proceeds from a promissory note issued to Lim Kok Thay.
• Resorts World Inc Pte Ltd (RWI): Lender. Senior secured loan agreements (RWI Bridge Loan, Amended RWI Loan, RWI Second Amended Bridge Loan) totaling $27,000k (net of discount), with warrants. Maturity extended to February 15, 2026. Loans fully satisfied on August 13, 2025, using proceeds from an Asset Purchase Agreement with Celeniv Pte. Ltd.
• Genting Innovation PTE LTD: Affiliate of Dragasac Limited. Distribution and manufacturing agreement for certain products in Asia markets, amended to include cell therapy products.
• Fountain Life Management LLC: Technology Services Agreement. Dr. Robert Hariri (CEO) and Dr. Peter Diamandis (director) are founding partners.
• Lim Kok Thay: Issued a promissory note for $6,812k on July 21, 2025, with a warrant. Note subsequently assigned to Celeniv Pte. Ltd.
• Celeniv Pte. Ltd.: Acquired intellectual property for $33,812k on August 13, 2025, and received assignment of Lim Kok Thay's promissory note. Entered into a License Agreement with Celularity.

Stakeholder Impact

• Shareholders: Face significant risk of further share price depreciation and dilution due to ongoing losses, liquidity concerns, and potential capital raises. The Nasdaq delisting notice adds substantial uncertainty and could impair liquidity of shares. The asset sale, while repaying debt, reduces the company's IP portfolio.
• Employees: Potential for further workforce reductions if the company fails to secure additional capital or is forced to curtail operations. Management's salary deferral/reduction indicates financial strain impacting executive compensation.
• Customers: Biobanking and degenerative disease customers may face uncertainty regarding long-term service continuity given the company's going concern doubt. Legal disputes with distributors and service providers could impact product availability or service quality.
• Creditors: While some major debt obligations have been repaid or extended, the company's overall liquidity issues and going concern doubt present ongoing risks. Defaults on smaller obligations and legal judgments indicate a strained ability to meet financial commitments.
• Regulatory Authorities: The Nasdaq delisting notice and Civil Investigative Demand highlight compliance and regulatory scrutiny, which could lead to further penalties or operational restrictions.

Next Steps

• File the Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, by August 31, 2025, to regain Nasdaq compliance.
• Continue to seek additional outside capital to fund operations and investments.
• Implement remediation plan to address material weaknesses in internal control over financial reporting throughout 2025 and beyond.
• Submit a 510(k) application for Celularity Tendon Wrap (CTW) in the second half of 2025.
• Advance development of FUSE Bone Void Filler for a 510(k) filing in the second half of 2026.
• Advance development of Celularity Placental Matrix (CPM) for a 510(k) filing in the second half of 2027.
• Assess opportunities in Florida and elsewhere to supply MLASCs cell therapy product candidates PDA 001 and PDA 002 to physicians.
• When sufficiently capitalized, complete safety and efficacy assessment for PDA 001 in Crohn's disease and PDA 002 in DFU to determine progress to Phase III clinical trials.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Continue to pursue legal action against Evolution Biologyx, LLC, et al. to recover $2.35 million in unpaid invoices.
• Address ongoing legal proceedings and judgments (e.g., TCWGlobal, Hackensack Meridian, Clinical Resource Network).
• Yorkville convertible promissory note maturity extended to October 15, 2025, conditional on 10-Q filings.
• Celeniv License Agreement: Company has an option to purchase Licensed Technology and Marks within five years.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial doubt about its ability to continue as a going concern, declining revenues, increasing operating losses, and critically low cash reserves. The Nasdaq delisting notice highlights significant compliance and operational failures. While recent capital raises and an asset sale provided temporary relief and debt repayment, these actions appear reactive to an acute liquidity crisis rather than indicative of strong operational health or strategic growth. The material weaknesses in internal controls further erode investor confidence. The lack of active development in cellular therapeutics due to liquidity constraints indicates a stalled core business. The accumulation of legal judgments and defaults on payments underscores a precarious financial position. Investors face high risk of further share price depreciation, dilution, or potential bankruptcy.

Keywords

Celularity, CELU, Biotechnology, Cell Therapy, Regenerative Medicine, Biomaterials, SEC Filing, 10-Q, Financial Results, Going Concern, Nasdaq Delisting, Liquidity, Debt, Private Placement, Asset Sale, Clinical Trials, Intellectual Property, Risk Factors, Corporate Governance, Financial Reporting, Healthcare, Pharmaceuticals, Biovance, Interfyl, Rebound, Placental-derived